Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Fineline Cube Jan 14, 2026
Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Fineline Cube Jan 14, 2026
Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
Company Drug

SCG Cell Therapy’s SCG101 Receives Tacit Approval for Cholangiocarcinoma Clinical Trial in China

Fineline Cube Nov 23, 2023

China’s Center for Drug Evaluation (CDE) website has indicated that SCG Cell Therapy Pte. Ltd’s...

Company Drug

Akeso Biopharma’s Cadonilimab Meets Primary Endpoint in Phase III Cervical Cancer Study

Fineline Cube Nov 23, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that its Phase III AK104-303 study for cadonilimab...

Company Drug

RemeGen’s Telitacicept Receives Full Approval for Systemic Lupus Erythematosus in China

Fineline Cube Nov 23, 2023

China-based pharmaceutical company RemeGen (HKG: 9995) has announced the conversion of conditional approval to complete...

Company Deals

Boehringer Ingelheim Acquires T3 Pharmaceuticals to Boost Immuno-Oncology Portfolio

Fineline Cube Nov 23, 2023

Germany’s Boehringer Ingelheim has announced the purchase of Switzerland-based biotechnology firm T3 Pharmaceuticals this week,...

Company Drug Legal / IP

Bayer Halts Late-Stage Trial for Asundexian After Underperformance

Fineline Cube Nov 23, 2023

Germany-headquartered Bayer (ETR: BAYN) announced the termination of a late-stage trial for its antithrombotic candidate...

Company Drug

Brii Biosciences’ BRII-179 Vaccine on Track for Breakthrough Therapy Designation in China

Fineline Cube Nov 23, 2023

China’s Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137),...

Company Deals

Venus Medtech Partners with Valgen Holding on DragonFly Valve System

Fineline Cube Nov 23, 2023

China-based Venus Medtech (Hangzhou) Inc., (HKG: 2500), has entered into a strategic partnership with Valgen...

Company Deals

Oculotronics Secures Pre-Series A Funding for Ophthalmic Surgical Robotics

Fineline Cube Nov 23, 2023

Oculotronics, a Guangzhou-based developer of ophthalmic surgical robots, has reportedly raised tens of millions of...

Company Drug

Sumitomo Pharma Receives Chinese Approval for Xenleta to Treat Pneumonia

Fineline Cube Nov 23, 2023

Japan-based Sumitomo Pharma Co., Ltd (OTCMKTS: DNPUF) has secured market approval in China for Xenleta...

Company Drug Medical Device

Gilead Announces Low-Carbon Bronchodilator Study for H1 2024

Fineline Cube Nov 23, 2023

Gilead Sciences Inc. (NASDAQ: GILD) has announced plans for a Phase III study in the...

Company Drug

Hunan Warrant Pharmaceutical’s ZG-001 Approved for Clinical Trial by NMPA

Fineline Cube Nov 22, 2023

Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving clinical...

Company Drug

VivaVision Biotech Inc. Receives FDA Approval for VVN461 Phase II Clinical Trial

Fineline Cube Nov 22, 2023

China’s VivaVision Biotech Inc. has announced that it has received approval from the US Food...

Company Drug

AnHeart Therapeutics and Innovent Biologics File Taletrectinib for Marketing Approval in China

Fineline Cube Nov 22, 2023

China’s Center for Drug Evaluation (CDE) has indicated on its website that taletrectinib, an ROS1/NTRK...

Company Deals

Genentech and NVIDIA Collaborate to Advance Drug Discovery with AI

Fineline Cube Nov 22, 2023

Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has entered into a collaboration...

Company Deals

MSD to Acquire Caraway Therapeutics for USD 610 Million to Boost Neurodegenerative Disease Portfolio

Fineline Cube Nov 22, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an agreement to purchase Caraway Therapeutics,...

Company Drug

Janssen Submits Indication Extension Application to FDA for Rybrevant in NSCLC Treatment

Fineline Cube Nov 22, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has filed an indication extension...

Company Deals

EC Healthcare Partners with Jiangxi Rimag Group to Expand Medical Imaging Services

Fineline Cube Nov 22, 2023

China-based EC Healthcare (HKG: 2138) has entered into a partnership with Jiangxi Rimag Group Co.,...

Company Deals

Dizal Pharmaceutical and Wuxi Gaofa Investment to Establish Joint Venture for Auto-Immune Disease Treatments

Fineline Cube Nov 22, 2023

China-based AstraZeneca (AZ, NASDAQ: AZN) spin-out, Dizal Pharmaceutical Co., Ltd (SHA: 688192), has entered into...

Company Deals

BeiGene Ltd Strikes Exclusive Global License Deal with Ensem Therapeutics for CDK2 Inhibitor

Fineline Cube Nov 22, 2023

China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a licensing...

Company Drug

Fosun Pharmaceutical’s FCN-437c filing Accepted for Review by China’s NMPA

Fineline Cube Nov 22, 2023

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has announced that the National...

Posts pagination

1 … 383 384 385 … 609

Recent updates

  • WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities
  • NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development
  • AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
  • Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
  • WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.